<- Go Home

Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.

Market Cap

CAD 232.8M

Volume

41.8K

Cash and Equivalents

CAD 9.5M

EBITDA

CAD 12.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CAD 21.4M

Profit Margin

80.78%

52 Week High

CAD 14.09

52 Week Low

CAD 3.80

Dividend

N/A

Price / Book Value

2.35

Price / Earnings

14.38

Price / Tangible Book Value

-82.55

Enterprise Value

CAD 264.0M

Enterprise Value / EBITDA

20.85

Operating Income

CAD 9.9M

Return on Equity

17.98%

Return on Assets

5.05

Cash and Short Term Investments

CAD 9.5M

Debt

CAD 40.8M

Equity

CAD 98.9M

Revenue

CAD 26.5M

Unlevered FCF

-CAD 78.5M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches